BACE1 and Alzheimer disease: Verubecestat (5) was the first BACE-1 inhibitor to enter phase 3 clinical trials for the treatment of amnestic mild cognitive impairment and prodromal AD, which means that it would influence the deposition of Aβ before the appearance of dementia symptoms.